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is economically efﬁcient with regard to reducing heart disease in
The Netherlands when given routinely to all patients following
PCI.
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OBJECTIVE: To assess cost-effectiveness of ezetimibe 10mg
(EZ10) co-administration with simvastatin versus a simvastatin
dose titration strategy in CHD patients who do not attain cho-
lesterol goal (TC < 5mmol/L) with simvastatin monotherapy.
METHOD: A decision-analytic model was developed to project
lifetime costs and beneﬁts of lipid therapy. Clinical trial data
were used to estimate TC reductions for different treatment
strategies. The effect of TC reductions on CHD event rates was
estimated using Framingham equations and Hungarian National
Statistics data on nonCHD-related mortality. Direct costs of
CHD events in Hungary, Hungarian prices for simvastatin and
EZ 10 price (based on German EZ10 price) were used to project
lifetime costs. The model was run for a population consisting of
138 CHD patients who are currently treated with simvastatin in
an observational Lipid Lowering Treatment study conducted in
Hungary, and had not reached goal at the TC measurement after
minimum 60 days of treatment. RESULTS: For these patients
(mean age 62.9 years, 51% male, lipid proﬁle on simvastatin
LDL-C 3.55mmol/l, TC 5.99mmol/l, HDL 1.44mmol/l, triglyc-
erides 2.40mmol/l), EZ10 co-administered with simvastatin
compared to simvastatin titration is projected to increase life
expectancy by 0.69 years with a discounted C/LY of 14,891€ and
the discounted C/QALY’s of 14,827€. CONCLUSIONS: Treat-
ment with EZ10 co-administered with simvastatin for CHD
patients not at goal is projected to be a more cost-effective alter-
native to simvastatin titration which is substantially under the
limit C/LY of 30,000€.
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OBJECTIVES: Numerous clinical studies have demonstrated the
safety and effectiveness of radiofrequency catheter ablation for
treatment of ventricular tachycardia (VT). The objective was to
evaluate the cost effectiveness of catheter ablation relative to
drug therapy to treat frequent recurrence of VT among patients
with structural heart disease. METHODS: We calculated the
incremental cost effectiveness of catheter ablation relative to
daily amiodarone treatment over various time horizons up to 5
years using a decision analytic Markov model (DATA 4.0TM,
TreeAge Software Inc.). Costs were based on a third party payer’s
perspective using 2004 Medicare reimbursement schedules and
discounted average wholesale drug prices. Model parameters,
adverse event rates, and utility weight estimates were obtained
from randomized clinical trial literature and expert opinion.
Costs and effects were discounted at 3% annually and sensitiv-
ity analyses were performed. The model analyzed the outcomes
and resource utilization of a hypothetical cohort of 10,000
patients with structural heart disease and implantable car-
dioverter-deﬁbrillators who experience frequent VT episodes.
RESULTS: Ablation consistently produced greater quality
adjusted life years (QALYs) compared to amiodarone in analy-
ses of 1 to 5 years. The incremental QALYs of ablation relative
to amiodarone at 1,2 and 3-years are 0.477, 0.82 and 1.05. The
average 1, 2, and 3-year costs for ablation ($14,000, $14,760,
$15,330) are higher compared to amiodarone ($10,760,
$12,870, $14,760). However, over a 5-year time horizon, the
average cost of ablation is less than amiodarone. The incremen-
tal cost-effectiveness ratio of ablation relative to amiodarone
decreases from $81,340 at 1 year to $6392 at 3 years. By 3.6
years, ablation dominates amiodarone. CONCLUSIONS:
Catheter ablation treatment of VT becomes increasingly cost
effective compared to drug therapy as the time horizon increases
and after 3.6 years, ablation is less costly and more effective than
amiodarone therapy.
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OBJECTIVES: LIFE was a double-masked, randomized trial of
losartan vs. atenolol in 9193 patients with essential hypertension
and LVH ascertained by electrocardiography. Losartan reduced
the primary composite endpoint of cardiovascular death,
myocardial infarction, or stroke by 13% (p = 0.021) and reduced
the risk of stroke by 25% (p = 0.001), despite a similar degree
of blood pressure control. Our objective was to assess the cost-
effectiveness of losartan compared with atenolol in hypertensive
patients with LVH, from the perspective of the Spanish Health
Care system. METHODS: Losartan and atenolol utilisation
within the trial period and lifetime direct medical costs follow-
ing a stroke in Spain were combined with estimates of reduction
in life expectancy following stroke. The cumulative incidence of
stroke and study medication utilization after 5.5 years of patient
follow-up were separately estimated, adjusting for baseline
degree of LVH and Framingham risk score. To estimate per
patient lifetime stroke costs, we multiplied the cumulative inci-
dence of stroke by the lifetime direct medical cost attributable to
stroke. All costs and beneﬁts are in 2004 Spanish prices dis-
counted at 3% annually. RESULTS: Losartan reduced stroke-
related cost by 270€ per patient due to a lower cumulative
incidence of stroke at 5.5 years (4.9% vs. 6.5%; p = 0.003). Net
costs were 1626€ higher per patient over 5.5 years for losartan
compared with atenolol. The number of life-years gained (LYG)
by preventing a stroke was 5.6 years, resulting in 0.090 (dis-
counted) LYG per patient with losartan. The estimated cost per
LYG for losartan was 18,147€ (95% CI: 10,127, 46,724) which
is well within bench-mark values (30,000€/LYG) for accepted
cost effective interventions in Spain. The probability of the cost-
effectiveness ratio falling below a threshold of 30,000€/LYG was
0.88. CONCLUSIONS: Treatment with losartan compared with
atenolol over a 5.5 year period is, based on the cost per LYG, a
cost-effective intervention in Spain.
